Background: Eptinezumab is a preventive migraine
treatment approved in the US. We evaluated the impact of eptinezumab on
acute headache medication (AHM) use in patients diagnosed with chronic
migraine (CM) and medication-overuse headache (MOH) in PROMISE-2.
Methods: PROMISE-2 randomized patients with CM to
eptinezumab 100mg, 300mg, or placebo for 2 intravenous doses administered
every 12 weeks. Trained investigators diagnosed MOH at screening using
3-month medication history and ICHD-3b criteria. Endpoints included
days/month of any AHM use (days of ≥1 medication class), total AHM use
(summed days for each medication class), and triptan use over Weeks 1-12 and
13-24. AHM classes included triptan, ergot, opioid, simple analgesic, and
combination analgesic. Results: Of 1072 PROMISE-2
patients, 431 (40.2%) were diagnosed with MOH (100mg, n=139; 300mg, n=147;
placebo, n=145). During the 28-day baseline period, mean days of any AHM was
~16.4, total AHM was ~20.4, and triptan was ~8.9 across treatment arms. Over
Weeks 1-12, mean days/month of any AHM was 8.8 (100mg), 9.9 (300mg), and
11.8 (placebo); total AHM was 10.8, 12.2, and 14.8; triptan was 4.3, 4.4,
and 6.4. Similar or lower rates were observed over Weeks 13-24.
Conclusions: In patients diagnosed with both CM
and MOH, eptinezumab treatment reduced AHM use.